Pancreatic Cancer Research

ResearcherStavanger University HospitalActive in the last 2 years

Oddmund Nordgård

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5847-6752; OpenAlex author ID A5005856709. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper

Papers 9

  1. Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragm… Last author DOI 10.1002/1878-0261.70116↗
  2. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiol… Last author DOI 10.1002/1878-0261.13472↗
  3. Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-3526↗
  4. Extracellular vesicles as a potential source of tumor-derived DNA in advanced pancreatic cancer. Last author DOI 10.1371/journal.pone.0291623↗
  5. Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study. Co-author DOI 10.1186/s12885-022-09714-x↗
  6. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-5195-7↗
  7. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Last author DOI 10.1186/s12967-018-1677-2↗
  8. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.molonc.2015.11.012↗
  9. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. First author DOI 10.1002/ijc.28134↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kjersti Tjensvoll · 9 shared papers, 2014–2025 · strength 1.25
  2. Bjørnar Gilje · 7 shared papers, 2016–2025 · strength 1.09
  3. Morten Lapin · 7 shared papers, 2016–2025 · strength 1.09
  4. Karin Hestnes Edland · 4 shared papers, 2022–2025 · strength 0.75
  5. Rune Smaaland · 4 shared papers, 2014–2022 · strength 0.35
  6. Milind M. Javle · 2 shared papers, 2016–2018 · strength 0.13
  7. Dag Hoem · 1 shared paper, 2019 · strength 0.09
  8. Man Hung Choi · 1 shared paper, 2019 · strength 0.09
  9. Khadija El Jellas · 1 shared paper, 2019 · strength 0.09
  10. Anders Molven · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.